Effectiveness of Noradrenaline and Albumin vs. Terlipressin and Albumin in Treating Hepatorenal Syndrome in Patients of Chronic Liver Disease
Year: 2025
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Objective: To compare the efficacy of noradrenaline and albumin versus terlipressin and albumin in the treatment of hepato-renal syndrome in patients with chronic liver disease. Methods: This was a randomized controlled trial conducted from 2nd August 2022 to 1st February 2023 at the Department of Medicine & Gastroenterology, Medical unit III, Services Hospital Lahore. A total of 70 patients of age 18 to 70 years, both genders, diagnosed with chronic liver disease (CLD) having HRS were included. Patients with chronic kidney disease (CKD), history of ischemic heart disease, arrhythmias or cardiomyopathy were excluded. Group A received Inj. Terlipressin 1mg x 6 hourly along with Inj. Albumin 1 mg/kg on day 1 and then 20 mg/day. Group B received Nordrenaline initially 1 mg/hour along with Inj. Albumin 1 mg/kg on day 1 and then 20mg/day. Patients were followed for 48 hours. If there was decline of serum creatinine < 1.5 mg/dl within 48 hours, then efficacy was labeled. Results: In our study, efficacy of noradrenaline and albumin was 80.0% versus 37.14% in terlipressin and albumin in treatment of hepato-renal syndrome in patients of CLD. Conclusion: This study concluded that efficacy of noradrenaline and albumin is better than terlipressin and albumin in treatment of hepato-renal syndrome in patients of chronic liver disease.
Authors: Hunza Malik, Muhammad Arif Nadeem, Abdul Waheed, Tabish Raza
Institution: Services Institute of Medical Sciences
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4408374180